Amyloid Fibrils Share a ‘Light’ Load
Stacked together, amyloid subunits absorb more light than they do as monomers. Are there implications for fibril detection?
ALL NEWS
70 RESULTS
Sort By:
- Most Recent
- Most Commented
Parkinson’s Antipsychotic Looks Good in Phase 3 Trial
Phase 3 trial results suggest pimavanserin tempers psychosis in people with Parkinson’s.
Opening the Doors to Clinical Trial Data
New regulatory initiatives will soon make clinical trial data more publicly available than ever, but industry and other groups warn that the move could endanger patient privacy and lead to misuse of data.
Researchers Revel in C9ORF72 Advances at RNA Symposium
The latest news on C9ORF72 includes a genetic modifier, various animal models, and a potential treatment to untangle stable, guanine-based structures formed by expanded repeats.
Imaging Reveals Amyloid Up To a Year After Traumatic Brain Injury
A proof-of-concept study suggests that amyloid imaging will offer insights into traumatic brain injury.
Profilin-1 Links Cytoskeleton and RNA Aggregation in ALS
Researchers find an actin-binding protein in stress granules, linking the cytoskeleton and RNA sequestration in the pathology of amyotrophic lateral sclerosis.
Paper Alert: TDP-43 Mouse No Model to Test ALS Therapeutics
A mouse with TDP-43 proteinopathy looks to be an unlikely model for testing amyotrophic lateral sclerosis drugs.
FDA Approves a Second Amyloid Imaging Agent
The FDA has approved a second tracer, flutemetamol, for PET imaging of amyloid plaques in the brain.
The Four Stages of TDP-43 Proteinopathy
Researchers propose four stages of TDP-43 pathology based on the spread of the protein through the brain.
Blocking a MicroRNA Slows Motor Neuron Disease in Mice
With several microRNAs being overly active in ALS, an antisense therapy to one slows the disease in mice, apparently by reducing neuroinflammation.
Turning to the Internet for Alzheimer’s Trial Volunteers
The Internet is poised to play a growing role in recruiting for Alzheimer’s clinical trials.
Do Tau Tracers Track Cognitive Decline in Disease?
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
Growth Factor Therapy: Safe in Phase 1, Awaiting Efficacy Data
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.
Society for Neuroscience Annual Meeting 2013
Researchers Revel in C9ORF72 Advances at RNA Symposium Profilin-1 Links Cytoskeleton and RNA Aggregation in ALS The Four Stages of TDP-43 Proteinopathy Blocking a MicroRNA Slows Motor Neuron Disease in Mice Glial Cells Refine Neural Circuits Innate Immune
Patient Engagement in Clinical Trials
A Conference Devoted to Better Engaging Clinical Trial Volunteers Turning to the Internet for Alzheimer’s Trial Volunteers Patient Engagement in Clinical Trials
Current Filters
- Date Range : Sep 2013 to Dec 2013 x